Le Lézard
Classified in: Health
Subjects: DIS, AVO, CFG

Calling on all federal parties: Canada needs a fully-funded national dementia strategy


Alzheimer Society campaign encourages Canadians to speak out

TORONTO, Sept. 9, 2019 /CNW/ - The Alzheimer Society is urging Canadians to get involved in the federal election by writing their candidates and asking them to commit to supporting a fully-funded national dementia strategy. 

This past June, the Government of Canada released the country's first-ever national dementia strategy to address the overwhelming scale, impact and cost of dementia in Canada. The 2019 federal budget included a commitment of $50 million over five years to support the strategy's implementation. 

"Canada's national dementia strategy is an important first step toward making life better for the more than half a million Canadians living with dementia today," says Pauline Tardif, CEO of the Alzheimer Society of Canada. "But like any strategy, it must be fully-funded to make a difference. The federal government's initial investment is a good start, but much more is needed in order to bring the strategy to fruition."

No matter which party forms government this fall, dementia must remain a top priority. Each year, dementia costs the economy and health care system more than $10.4 billion. As our population ages, we simply cannot afford to ignore dementia.

"In less than 12 years, the number of Canadians living with dementia?and the cost to care for them?will nearly double," says Tardif. "Family members, hospitals and long-term care homes are already stretched beyond their limits. We need to start implementing the national dementia strategy right now to ensure that the growing number of Canadians affected by dementia receive the care and support they deserve."

As part of the campaign, the Society has provided an online letter-writing tool along with other resources for Canadians to speak out and let their candidates know that they will be voting with dementia as a priority this October. Visitors to the website can also read stories from researchers and people with lived experience on how the national dementia strategy will make a difference.

To learn more and get involved, visit alzheimer.ca/Election2019.

About the Alzheimer Society
The Alzheimer Society is Canada's leading nationwide health charity for people living with Alzheimer's disease and other dementias. Active in communities across Canada, the Society provides information, programs and services, and raises funds for research to better understand the causes of dementia, improve treatment and care, and to find a cure.

Quick facts

SOURCE Alzheimer Society of Canada


These press releases may also interest you

at 08:05
Gilead Sciences, Inc. today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide...

at 08:05
Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (MDNAF: OTCQB), a clinical-stage immunotherapy company focused on the development of engineered cytokines, today announced a CA$20 million investment by RA Capital Management, a multi-stage...

at 08:02
Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for the treatment and prevention of bleeds and perioperative...

at 08:00
Citius Pharmaceuticals Inc. ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive...

at 08:00
Florida Cancer Specialists & Research Institute, LLC (FCS) President & Managing Physician Lucio N. Gordan, MD will serve as a panelist at the 2024 Oncology Fellows & Faculty Forum in Miami, sponsored by PrecisCa and the Community Oncology Alliance...

at 08:00
Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio, renal and metabolic diseases, today announced its participation at two prestigious medical conferences: the American...



News published on and distributed by: